TW202035443A - 抗金黃色葡萄球菌抗體的組合 - Google Patents

抗金黃色葡萄球菌抗體的組合 Download PDF

Info

Publication number
TW202035443A
TW202035443A TW108136341A TW108136341A TW202035443A TW 202035443 A TW202035443 A TW 202035443A TW 108136341 A TW108136341 A TW 108136341A TW 108136341 A TW108136341 A TW 108136341A TW 202035443 A TW202035443 A TW 202035443A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
binding fragment
staphylococcus aureus
binds
Prior art date
Application number
TW108136341A
Other languages
English (en)
Chinese (zh)
Inventor
克里絲汀 塔卡茲克
布里特 希爾曼
群 杜
梅麗莎 丹舒羅德
泰勒 柯恩
Original Assignee
美商麥迪紐有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商麥迪紐有限責任公司 filed Critical 美商麥迪紐有限責任公司
Publication of TW202035443A publication Critical patent/TW202035443A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW108136341A 2018-10-09 2019-10-08 抗金黃色葡萄球菌抗體的組合 TW202035443A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862743490P 2018-10-09 2018-10-09
US62/743,490 2018-10-09
US201962833297P 2019-04-12 2019-04-12
US62/833,297 2019-04-12

Publications (1)

Publication Number Publication Date
TW202035443A true TW202035443A (zh) 2020-10-01

Family

ID=70051346

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108136341A TW202035443A (zh) 2018-10-09 2019-10-08 抗金黃色葡萄球菌抗體的組合

Country Status (11)

Country Link
US (2) US11168133B2 (enExample)
EP (1) EP3864041A2 (enExample)
JP (1) JP2022512647A (enExample)
KR (1) KR20210072057A (enExample)
CN (1) CN113164602A (enExample)
AU (1) AU2019357983A1 (enExample)
BR (1) BR112021006622A2 (enExample)
CA (1) CA3115633A1 (enExample)
MX (1) MX2021004173A (enExample)
TW (1) TW202035443A (enExample)
WO (1) WO2020076789A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
EP3840838A2 (en) 2018-07-24 2021-06-30 MedImmune, LLC Antibody directed against s.aureus clumping factor a (clfa)
JP2022512647A (ja) 2018-10-09 2022-02-07 メディミューン，エルエルシー 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
CN113015745B (zh) 2018-10-09 2025-02-11 免疫医疗有限责任公司 针对金黄色葡萄球菌白细胞毒素的抗体
US12264194B2 (en) 2019-03-13 2025-04-01 Medimmune, Llc Decreasing Staphylococcus aureus infections in colonized patients
IL297969A (en) * 2020-05-07 2023-01-01 Pliant Therapeutics Inc Treatment of respiratory diseases with amino acid compounds
CN117771379B (zh) * 2023-10-25 2024-08-30 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CN101928343B (zh) 2001-01-26 2014-09-17 英希比泰克斯公司 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
ES2338105T3 (es) 2003-05-14 2010-05-04 Kenta Biotech Ag Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa.
CN1324049C (zh) 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
AU2007259415B2 (en) 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EA201170028A1 (ru) 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US20120034212A1 (en) 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
JP6031029B2 (ja) 2010-05-05 2016-11-24 ニューヨーク・ユニバーシティ 黄色ブドウ球菌ロイコシジン、その治療用組成物、および使用
US9527905B2 (en) 2011-02-08 2016-12-27 Medimmune, Llc Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
CA2890385C (en) 2012-11-06 2022-07-12 Medimmune, Llc Methods of treating s. aureus-associated diseases
SG11201503232TA (en) 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
WO2015055814A1 (en) 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
ES2869459T3 (es) 2014-05-16 2021-10-25 Medimmune Llc Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
KR20170136637A (ko) * 2015-04-17 2017-12-11 알사니스 바이오사이언시스 게엠베하 항-스타필로코커스 아우레우스 항체 배합 제제
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
EP3840838A2 (en) 2018-07-24 2021-06-30 MedImmune, LLC Antibody directed against s.aureus clumping factor a (clfa)
JP2022512647A (ja) 2018-10-09 2022-02-07 メディミューン，エルエルシー 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
CN113015745B (zh) 2018-10-09 2025-02-11 免疫医疗有限责任公司 针对金黄色葡萄球菌白细胞毒素的抗体

Also Published As

Publication number Publication date
AU2019357983A1 (en) 2021-05-27
US11168133B2 (en) 2021-11-09
US20200109189A1 (en) 2020-04-09
MX2021004173A (es) 2021-09-08
JP2022512647A (ja) 2022-02-07
US20220089699A1 (en) 2022-03-24
KR20210072057A (ko) 2021-06-16
WO2020076789A2 (en) 2020-04-16
WO2020076789A3 (en) 2020-10-22
EP3864041A2 (en) 2021-08-18
BR112021006622A2 (pt) 2021-07-20
CA3115633A1 (en) 2020-04-16
CN113164602A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US11168133B2 (en) Combinations of anti-Staphylococcus aureus antibodies
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
US11970527B2 (en) Antibody directed against S. aureus clumping factor A (ClfA)
JP6473746B2 (ja) 交差反応性黄色ブドウ球菌抗体配列
US11578119B2 (en) Antibodies directed against Staphylococcus aureus leukotoxins
CN104640878A (zh) 交叉反应的金黄色葡萄球菌抗体
JP2017505758A (ja) 黄色ブドウ球菌のｌｕｋｇｈ（ｌｕｋａｂ）毒素に対する抗体及び抗体配列
CN107614517B (zh) 抗感染疾病的抗体
RU2804815C2 (ru) Комбинации антител к staphylococcus aureus
WO2021186398A1 (en) Anti-klebsiella pneumoniae antibodies and uses thereof
TWI902669B (zh) 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
RU2805969C2 (ru) Антитела, направленные против лейкотоксинов staphylococcus aureus